The Asahi Glass Foundation Announces the Results of the 32nd Annual “Questionnaire on Environmental Problems and the Survival of Humankind”
The Asahi Glass Foundation (Chairman: Takuya Shimamura) has conducted an annual survey with environmental experts from around the world since 1992. This year, we sent the questionnaire to 202 countries around the world, and received responses from 1,805 people in 130 countries. Below are the main points from this year’s questionnaire results. Further details are available in the report of the “32nd Annual Questionnaire on Environmental Problems and the Survival of Humankind,” or online at the Foundation’s web site (https://www.af-info.or.jp/en/), starting at 11 a.m. JST on September 6, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905353048/en/
Change in the Time on the Environmental Doomsday Clock Since 1992 (Graphic: Business Wire)
- The time on the Environmental Doomsday Clock has turned back for three consecutive years since 2021, striking 9:31 in 2023.
- Looking at the time on the Clock around the world, the Clock went back more than 10 minutes compared to last year in South America, Western Europe, and the Middle East; but it moved forward more than 20 minutes in Mexico, Central America & the Caribbean, and Eastern Europe & former Soviet Union.
- "Climate Change" has been the top environmental issue since 2011 that the respondents worldwide have had on their minds in determining the time on the Clock.
- With regard to transitioning to a decarbonized society, the results showed an equal lack of progress in “Policies and Legal System” and “Social Infrastructure (Funds, Human Resources, Technologies, and Facilities)” compared with “Public Awareness.”
- Regarding the world’s problems, “13. Climate Action” was the most selected as the goal that respondents are most concerned about, followed by “1. No Poverty,” and “16. Peace, Justice and Strong Institutions.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905353048/en/
Contact information
THE ASAHI GLASS FOUNDATION
Toshihiro Tanuma, PhD
TEL: +81 3 5275 0620
E-mail: post@af-info.or.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses21.9.2023 17:00:00 EEST | Press release
Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™). AnQlar is a nanoparticle intended to help prevent the spread of negatively charged viruses such as COVID-19 and influenza via intranasal spray, and has shown to inhibit the ability of the virus to replicate at non-toxic concentrations. In development since 2022, the project has so far seen the completion of safety assessment utilizing intranasal administration at Altasciences’ preclinical site in Columbia, MO. A cardiovascular study was also completed at Altasciences’ preclinical facility in Scranton, PA. Bioanalytical sample analysis for the GLP studies is currently ongoing. “We
Nitek: End of the Road for Copycats21.9.2023 16:00:00 EEST | Press release
Nitek, Inc. (“Nitek”), a pioneering American company in UV LEDs, has announced that it filed a patent infringement lawsuit against Photon Wave Co., Ltd. (“Photon Wave”), a Korean UV LED manufacturer in the Eastern District of Texas. In the complaint, Nitek asserts that LED products of ams OSRAM, a German LED company, use Photon Wave’s infringing LEDs. Nitek also contends that Photon Wave has failed to cease selling infringing products, even after getting continuous warning notices of the patent infringement, and therefore Nitek is not only seeking a permanent injunction against the sales of infringing products but also pursuing 3 times damages for willful patent infringement. Nitek has previously successfully won its patent lawsuit against another international LED maker, and continues its enforcement against other infringers. Sensor Electronic Technology, Inc. (“SETi”), an affiliate of Nitek, has also obtained a permanent injunction for patent infringement against Bolb, Inc., a UV LED
Boomi Launches World Tour, Bringing Together Visionary Leaders and Industry Experts to Prepare Businesses for the AI Revolution21.9.2023 16:00:00 EEST | Press release
Boomi™, the intelligent connectivity and automation leader, today announced the Boomi World Tour, a premiere series of exclusive, in-person events bringing together Boomi customers, prospects, and partners to hear directly from Boomi leadership, industry experts, and visionaries on how organizations can leave complexity behind and synchronize everything, everywhere, with AI-driven integration and automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230921479137/en/ Boomi Launches World Tour, Bringing Together Visionary Leaders and Industry Experts to Prepare Businesses for the AI Revolution (Graphic: Business Wire) The Boomi World Tour is a series of 10 events over eight weeks, including three Partner Summits designed especially for Boomi partners, global systems integrators, and OEMs. The tour kicks off in Menlo Park, CA, October 3-4, 2023, where attendees will have opportunities to connect and learn throughout the tw
Hologic and Bayer Announce International Partnership to Deliver Comprehensive Contrast-Enhanced Mammography Package to Breast Imaging Facilities21.9.2023 15:30:00 EEST | Press release
Hologic Inc. (Nasdaq: HOLX) and Bayer today announced an international partnership to deliver contrast-enhanced mammography (CEM) solutions to improve the detection of breast cancer for women in multiple countries across the European, Canadian and Asia Pacific regions. CEM is a highly sensitive and relatively low-cost breast imaging modality that combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions.1 The partnership brings together the companies’ leading technologies (Hologic mammography gantries and Bayer CEM-approved injection systems) to enable the administration of contrast media during a mammography examination. With the new agreement, Bayer and Hologic aim to optimally support radiologists and their teams’ needs by providing a comprehensive product package along with the hands-on training needed to effectively implement CEM into their facility’s workflow. “Over the past several years, we’ve seen
ReNAgade Therapeutics Named to the 2023 Endpoints 1121.9.2023 15:00:00 EEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that it has been named as one of the Endpoints 11 companies of 2023, awarded by Endpoints News editor John Carroll to the most promising private biotechnology companies in the industry. “To be included as one of the Endpoints 11 top private biotech companies is not only a great honor for our young company, but also recognition from the industry of what we’ve already accomplished in the past 18 months toward our aim of overcoming the current limitations of RNA medicines,” said Amit D. Munshi, Chief Executive Officer of ReNAgade. “The Company has continued to grow since our $300 million Series A financing round, building on our world-class, multidisciplinary team that is dedicated to innovating delivery technology and bringing an array of genomic medicine tools under one roof. We look forward to expanding the reach of RNA medicine beyond what was previously thought possible, beginning wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom